The UK and US have secured a important trade agreement that will guarantee zero levies on British pharmaceutical exports entering the US market.
Key Provisions of the Pact
As part of the deal, the UK has committed to increase expenditure on medicines through the NHS. This commitment ensures that import taxes on these key goods will be held at zero for a duration of the next three years.
This agreement comes after previous statements to dramatically increase import taxes on patented drug products, with increases discussed reaching 100%.
"This arrangement with the United Kingdom reinforces the worldwide climate for new treatments and introduces much-needed equity to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Impact
Medicines constitute one of the Britain's most significant export categories to the United States, which is clearly the largest destination for large British pharmaceutical firms.
Statistics indicate that in the year to the end of last September, the UK exported pharmaceutical products valued at billions to the US. This amount represented nearly one-fifth of all goods exports in that period.
"This guarantee secures employment, boosts funding and sets the stage for the UK to emerge as a international leader for medical research," a government official remarked.
Specific British Pledges
The deal entails several specific commitments from the British government:
- Revised Affordability Limit: The UK will raise the cost ceiling at which it considers new treatments to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a target to increase overall NHS spending on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Rebate Cap: The sum manufacturers must return to the NHS to stay within budget will be limited at 15%. Last year, rebates exceeded twenty percent.
Recent Tensions
The deal takes place against a ongoing tension between the drug companies and the British authorities over medicine costs and approval rates.
These tensions were intensified by arguments that American consumers were charged a premium for the equivalent treatments than people in the Britain and the EU.
Recently, several significant drug company projects in the UK have been halted or abandoned, while substantial investments have been pledged toward American operations.
A senior figure stated that the NHS had to spend more on drugs, noting that its budget allocation on drugs had shrunk as a share of its resources over the past decade.
